Conspectus The zinc-dependent histone deacetylases (HDACs 1–11) belong to the
arginase-deacetylase superfamily of proteins, members of which share a common α/β fold …

Tubastatin A, a tetrahydro-γ-carboline-capped selective HDAC6 inhibitor (HDAC6i), was
rationally designed 10 years ago, and has become the best investigated HDAC6i to date. It …

Despite the applicability of histone deacetylase inhibitors (HDACis) for cancer treatment,
several works in the literature have shown that these inhibitors can be used in several other …

Histone deacetylase 6 (HDAC6) is an attractive drug development target because of its role
in the immune response, neuropathy, and cancer. Knockout mice develop normally and …

Evidence for research over the past decade shows that epigenetic regulation mechanisms
run through the development and prognosis of tumors. Therefore, small molecular …

Microtubules (MTs) mediate various cellular functions such as structural support,
chromosome segregation, and intracellular transport. To achieve this, the pivotal properties …

Mutations in the gene encoding MFN2 have been identified as associated with Charcot–
Marie–Tooth disease type 2A (CMT2A), a neurological disorder characterized by a broad …

Background: Diabetic nephropathy (DN) is one of the leading causes of chronic kidney
disease (CKD) worldwide, tubular injury is the driving force during the pathogenesis and …

Dual-or multitarget drugs have emerged as a promising alternative to combination therapies.
Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) …

Histone deacetylases (HDACs) are important modulators of epigenetic gene regulation and
additionally control the activity of non-histone protein substrates. While for HDACs 1–3 and 6 …